Hymon Patented Technology Paves Way in COVID-19 Rapid Detection


Hymon Patented Technology Paves Way in COVID-19 Rapid Detection

HymonBio is rooted in China, focusing on the research and development of precision medicine and POCT-related products, and holds a large number of patents and proprietary technologies. The R&D team has continuously expanded COVID-19 test reagent product lines, and actively and quickly responds to domestic and foreign market demands, contributing to China’s global epidemic control. Recently, HymonBio pas passed CE certification of COVID-19 Rapid Antigen Test and was quickly put into the global anti-epidemic efforts.



The COVID-19 Antigen Rapid Test Kit, independently developed by HymonBio, is used for in vitro qualitative detection of SARS-CoV-2 nucleocapsid protein antigens. Using noninvasive sampling methods, it takes only 15 minutes to complete a test. The product adopts HymonBio’s innovative patent technology: a test strip for quantitative detection of compounds and a detection method using lateral immunochromatography, authorized in 2019. Through this patented technology, sensitivity and specificity of detection has been greatly improved, with unique advantages in detecting SARS-CoV-2. By comparing clinical samples with PCR detection, sensitivity and specificity of viral detection were 96.97% and 99.29% respectively.

Product features:

       1. 15-minute rapid detection

       2. Simple operation, no special equipment required

       3. Noninvasive, simple sampling

       4. Suitable for large-scale rapid screening

       5. CE certified

Post time: Feb-16-2022